Heterogeneity in RAS mutations: One size does not fit all.

Open access · greenAbstract readComment

In one paragraph

Article in Science signaling, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it

0cells of the map it votes in

4citing papers in PubMed

0.7field-weighted citation impact, top 33% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

RESEARCH CHALLENGES IN STAGE III AND IV RAS-ASSOCIATED CANCERS: A Narrative Review of the Complexities and Functions of the Family ofBiology · 2025
Review
In-depth analysis of the interplay between oncogenic mutations and NK cell-mediated cancer surveillance in solid tumors.Oncoimmunology · 2024
Review
SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status.Proceedings of the National Academy of Sciences of the United States of America · 2023
Article
RAS signaling and immune cells: a sinister crosstalk in the tumor microenvironment.Journal of translational medicine · 2023
Review

4 · The record

Corrections and comments

Comment on
Functional and biological heterogeneity of KRAS2022

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Nancy E SealoverDepartment of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.ORCID 0000-0002-6463-5836

Robert L KortumDepartment of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.ORCID 0000-0002-1634-4882

Uniformed Services University of the Health Sciences · US

Funding

Isoform-specific signaling as a determinant of RAS-driven oncogenesisR01CA255232 · NCI · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI Robert Kortum · 2022 to 2026

$1.7M

Preventing Therapeutic Resistance in RAS-mutated Pediatric CancersR21CA267515 · NCI · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI KORTUM, ROBERT · 2022 to 2024

$389k

NCI NIH HHS R01 CA255232NCI NIH HHS R21 CA267515

6 · The paper itself

Abstract

Although oncogenic driver mutations in

Indexed as

Biological ProductsNeoplasmsHumansMutationProto-Oncogene Proteins p21(ras)Review Literature as TopicSignal TransductionBiological ProductsProto-Oncogene Proteins p21(ras)

Identifiers

PMID35944067

DOI10.1126/scisignal.adc9816

PMCPMC9750736

OpenAlexW4290779920

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.